Transforming biomarker development for cancer immunotherapy: Introducing the PhenoCode Signature approach

As cancer treatment evolves with the advent of new immunotherapies, it is crucial to accurately identify which patients will respond to these treatments. The tumor microenvironment (TME) has been shown to be a key factor in determining therapeutic responses across various cancer types. In this webinar, Dr Ning Ma, Sr. Applications Scientist at Akoya Biosciences, will discuss the latest tools for analyzing the TME and simplifying the process of developing predictive biomarkers. The PhenoCode™ Signature panels from Akoya Biosciences provides the right balance of content, flexibility, speed, and scalability needed to advance biomarker development. Discover how the PhenoCode Signature approach is revolutionizing the way biomarkers are developed for immunotherapy response.

Key learning objectives

• Understand the predictive limits of current biomarkers for immunotherapy and the power of spatial signatures
• Discover the power of PhenoCode Signature panels in accelerating spatial phenotyping and spatial signature development
• Learn how to use PhenoCode Signature in a discovery-to-translational workflow to identify spatial signatures

Who should attend?

• Translational and clinical researchers in biopharmaceuticals, biotechs and CROs who are involved in biomarker development for cancer immunotherapies
• Immunologists, pathologists and cancer researchers seeking a deeper understanding of tumor heterogeneity and spatial phenotyping of tumor immune microenvironment

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.